Last reviewed · How we verify
RDX5791
At a glance
| Generic name | RDX5791 |
|---|---|
| Also known as | Tenapanor, AZD1722 |
| Sponsor | Ardelyx |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessing Tenapanor as a Treatment of CF-related Constipation. (PHASE3)
- A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults (PHASE3)
- Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation (PHASE4)
- A Novel Approach for Reducing Hyperoxaluria and Kidney Stone Risk. (PHASE4)
- 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs (PHASE2)
- Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years (PHASE3)
- Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C (PHASE3)
- Tenapanor in Synucleinopathy-Related Constipation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RDX5791 CI brief — competitive landscape report
- RDX5791 updates RSS · CI watch RSS
- Ardelyx portfolio CI